Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

This study is testing talazoparib — a PARP inhibitor that blocks cancer cells from repairing their DNA — in adult patients with advanced solid tumors who have specific inherited or acquired mutations in DNA repair genes. **You may be eligible if...** - You are an adult with a confirmed solid tumor that has progressed after at least one prior standard treatment (or for whom no standard treatment exists) - Your tumor or blood has a documented mutation in a gene involved in DNA damage repair (such as BRCA1, BRCA2, PALB2, ATM, or related genes) - The mutation was identified through a recognized genetic testing laboratory - Your organ function is adequate to tolerate the study drug **You may NOT be eligible if...** - You do not have a qualifying DNA repair gene mutation - You have had prior treatment with a PARP inhibitor - You have active brain metastases that are not stable - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.